Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and older to protect ...

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

In years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

What is this silent virus that endangers Filipino Seniors with comorbidities? Respiratory Syncytial Virus (RSV) is not just another cold or flu—it is potentially life- threatening for seniors ...

Olympic gold medal-winning gymnast Shawn Johnson East has had respiratory syncytial virus-related ... [+] experiences with all 3 of her children. Now she's trying to warn others about RSV.

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department ...

In addition to flu and COVID-19 shots, respiratory syncytial virus (RSV) vaccines are available for the most vulnerable. Here’s what you need to know. While most people who contract RSV can ...

NEW YORK, October 22, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...

The FDA has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo for adults ages 18 to 59 who are at an increased risk of developing lower respiratory tract disease (LRTD).

2:05 Access to infant RSV protection differs across Canada Some Ontario doctors have started offering a free shot that can protect babies from respiratory syncytial virus while Quebec will begin ...